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A B S T R A C T
Purpose: To describe the questions addressed by participants and physicians to the International Registry
of Antiepileptic Drugs and Pregnancy centre in the Netherlands (EURAP-NL).
Methods: All incoming questions during the study period were systematically inventoried. Character-
istics of the inquirer, antiepileptic drugs (AEDs) indicated, question topic, indication for which AEDs were
(to be) prescribed, and timing of the question relative to pregnancy were evaluated.
Results: Healthcare professionals posed the majority of questions. Lamotrigine, levetiracetam, valproate
and carbamazepine were the drugs most frequently referred to. Common reasons to contact EURAP-NL
were congenital malformation risks associated with speciﬁc AEDs, requests for information updates
when available guidelines were considered lacking, and concerns regarding breastfeeding while using
AEDs.
Conclusions: There is an evident demand for additional information regarding AEDs and pregnancy.
Pregnancy registries like EURAP can be a useful tool to identify information deﬁcits and may serve as an
information source for the development of guidelines to facilitate common practice among healthcare
professionals.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Seizure
jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz1. Introduction
A rational management of antiepileptic treatment is of major
importance for women in the context of pregnancy and lactation.
In utero exposure to antiepileptic drugs (AEDs) is estimated to
increase the risk of major congenital malformations in the
newborn two to three times relative to the general population.1
A substantial number of pregnant women (approximately ﬁve out
of 1000) are diagnosed with epilepsy. Women with epilepsy need
to adhere to antiepileptic treatment.2 Since AEDs are prescribed for
other indications as well, the proportion of pregnancies exposed to
AEDs is even higher. In a survey among practicing neurologists and
psychiatrists from the UK, half of each specialty group reported
that AED-treated women of reproductive age represented one
quarter of their consultations within the past year.3 In order to
provide optimal treatment for women of reproductive ages,
information is critical for healthcare professionals especially when
balancing the beneﬁcial effects of drug treatment against potential
negative effects of AEDs on pregnancy outcome.4 Whereas
personal consultations are preferred in the case of patients’
medical questions,5 clinicians’ questions are best answered by* Corresponding author. Tel.: +31 88 7553800; fax: +31 88 7553801.
E-mail address: s.bulk@umcutrecht.nl (S. Bulk).
1059-1311/$ – see front matter  2012 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2012.06.011clear medical guidelines, and, when available, by additional
information from recent studies.
The teratogenic risk of AED therapy is present from the ﬁrst
weeks of pregnancy, often before the woman is aware of being
pregnant. Information should be provided proactively by healthcare
providers to all women of childbearing potential using AEDs in order
to accomplish treatment adjustments prior to conception.6 Clin-
icians should be aware that the teratogenic risks are (at least
partially) related to the type, dosage, and number of AEDs.7,8
Strategies to prevent teratogenic sequelae aim to achieve seizure
control with as few AEDs as possible, at the lowest effective dose. It is
recommended to limit the administration of old-generation AEDs
during pregnancy because potentially severe teratogenic effects are
associated with AEDs such as valproate and carbamazepine.9,10 On
the other hand, for newer generation AEDs such as lamotrigine and
levetiracetam, and for most, if not all, of AED combination therapy,
data available regarding their safety during pregnancy and lactation
are more sparse. While updates on management of women using
AED in pregnancy are often being released,11–14 the need for
information on the side of involved parties, patients as well as
clinicians, has not yet been determined adequately.
In this article, we deﬁned the information demand among
patients and clinicians in regard to the prescription and use of AEDs
during pregnancy and lactation. To this aim, we evaluated
enquiries concerning the use of AEDs to the International Registryvier Ltd. All rights reserved.
Fig. 1. Categories of antiepileptic drugs on which information has been requested.
LTG, lamotrigine; LEV, levetiracetam; CBZ, carbamazepine; VPA, valproate; OXC,
oxcarbazepine; BZD, benzodiazepine; TPM, topiramate; ESX, ethosuximide; GBP,
gabapentine; PGB, pregabaline; AED, antiepileptic drugs in general. Data labels
indicate the count of questions mentioning each drug category. Some questions
involved more than one drug, e.g., for comparison purposes.
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(EURAP-NL).
2. Materials and methods
The International Registry of Antiepileptic Drugs and Pregnancy
(EURAP) is the largest observational cohort study concerning the
use of AEDs in pregnancy.14,15 EURAP systematically records data
from pregnant women who use AEDs during pregnancy aiming to
estimate the relative risk of major foetal malformations associated
with the exposure to AEDs during pregnancy.
EURAP-NL commenced in 2001 under the coordination of the
Department of Clinical Genetics, located at the University Medical
Centre Utrecht. During the entire study period, coordinators of the
study centre have been available for participating physicians and
participants, as well as for the general community, to answer
questions concerning AED use in relation to pregnancy. Information
to healthcare professionals and (future) participants relied on most
recent literature reviews resulting from searches in medical
research and drug databases as well as on evidence from the EURAP
database. (Pregnant) women in need for information regarding their
personal treatment were advised to attend medical counselling with
their family physician or medical specialist in charge.
All incoming questions and the corresponding answers were
systematically inventoried. For analysis, the following data were
retrieved from each query: characteristics of the person submitting
the query, AEDs in question, topic of the query, prescription
indication of the AEDs, and timing of the question relative to a
pregnancy. Descriptive data are presented as frequencies and
counts (where appropriate).
A total of 222 consecutive questions were received by the
EURAP centre in the Netherlands from January 1, 2002 until
November 17, 2010 and they were paralleled by 1600 registered
pregnancies. Of all questions, four regarded participation to the
EURAP study, three concerned the teratogenicity of non-AEDs only
(i.e., sertraline and pimozide), and two did not mention any
medication at all. The remaining 213 questions referred to one or
more AEDs and were selected for analyses.
3. Results
Healthcare professionals as well patients asked for AED-related
information. Healthcare professionals posed questions most
frequently (64.3%, n = 137). Neurologists represented the majority
among the healthcare professionals (52.3% of all queries, n = 67),Table 1
An overview of topics on which questions were asked.
% Questions
Total = 213
Topic Example
35% Congenital malformation risks in foetus
of AED treated woman
Can observed malfor
13% General updates from literature
overviews and EURAP preliminary data
Is there new data av
9% Breastfeeding associated risks Does quantitative ev
lamotrigine?
8% Comparison between AEDs Given that therapeut
treatment choice bet
6% Vitamin supplementation Which is the recomm
newborn with spina 
5% Cognitive development risks Do autism spectrum 
from mothers who w
5% Pharmacological interactions with
hormonal medication
Should AED dose be 
fertilization procedu
5% Risks for pregnancy complications Is there a possible re
4% Dose adjustment Does the risk for con
combination?
10% Other –followed by gynaecologists/obstetricians (15.6%, n = 20) and
clinical geneticists (14.1%, n = 18). Only 5% (n = 7) of all queries
were addressed by psychiatrists. Approximately one-third of the
questions were asked by pregnant women using AEDs (32.4%,
n = 69) or by their relatives (3.3%, n = 7).
Fig. 1 gives an overview of the drug groups that elicited an
enquiry. Lamotrigine, followed by levetiracetam, valproate and
carbamazepine were most frequently mentioned. The most
frequently asked questions (34.7%, n = 74) concerned observed
malformations, or risk estimates of malformations in offspring of
AED treated women. Second most prevalent (13.5%, n = 28) were
requests to update information about speciﬁc AEDs. The latter
category of queries originated exclusively from clinicians. Ques-
tions regarding breastfeeding associated risks in the newborn
infant ranked as third (8.9%, n = 19). In 4 out of 213 questions,
participants explicitly stated that divergent counselling opinions
among different physicians had prompted their query. An
extensive list of topics is shown in Table 1.mations (e.g., micrognatia, mandibular hypoplasia) be ascribed to medication?
ailable about the safety and teratogenicity of levetiracetam?
idence exist about breastfeeding associated risks for the newborn in the case of
ic opinions from two neurologists are contradictory, which is the optimal
ween lamotrigine and carbamazepine?
ended dose of folic acid supplementation when previous pregnancies resulted in a
biﬁda?
disorders and delay in cognitive development occur more frequently in children
ere under AED treatment during pregnancy?
adjusted when used simultaneously with hormonal treatment during in vitro
re?
lationship between medication during the pregnancy and spontaneous abortion?
genital malformations decrease when lowering each drug dose within an AED
Fig. 2. Timing of the enquiry relative to the pregnancy as registered by EURAP. Solid
ﬁll – enquiries sent before and after pregnancy; crosshair patterns – enquiries sent
during pregnancy of patient. Total of questions mentioning that information was
needed for a particular pregnant woman is 177.
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patient (i.e., woman being treated with AEDs) such as drugs being
administered, main indication for treatment, patient’s intention to
conceive or pregnancy stage at the moment. The majority of these
questions referred to the choice of medication for the treatment of
an epilepsy syndrome (67.8%, n = 118). In addition, there was a
small proportion of questions that speciﬁcally mentioned treat-
ment indications other than epilepsy such as psychiatric disorders
(3.4%, n = 6) and chronic pain syndrome (2.3%, n = 4).
Where the pregnancy stage of the AED treated woman in
question was mentioned, queries inventoried during the ﬁrst
trimester of pregnancy were most prevalent. The more advanced
the pregnancy stage, the fewer questions were registered. More
than half of the questions were asked outside a pregnancy period of
the AED treated women, either before potential conception or after
delivery (Fig. 2). Notably, questions about teratogenic risks of AEDs
in offspring of patients (n = 71) were uniformly distributed across
the preconception (39.7%, n = 29) and postnatal period (31.5%,
n = 23).
4. Discussion
This is the ﬁrst study to evaluate frequently asked questions
regarding antiepileptic drug treatment in relations pregnancy and
breastfeeding. During the period analysed, EURAP-NL was con-
tacted by many of its participants and by clinicians who needed
additional, up to date information about AED use during pregnancy
and lactation. Information demand was extensive as revealed by
the various question topics with malformation risks, literature
updates and breastfeeding related risks being the most prominent.
Discordant with the general prescription pattern in the
Netherlands, the majority of questions addressed issues related
to new generation AEDs such as lamotrigine and levetiracetam.
The EURAP prescription ﬁgures over the period 1999–2010 show
that carbamazepine (belonging to old generation AED) was the
most frequently administered drug in monotherapy, followed by
lamotrigine and valproate.16 While lamotrigine and levetiracetam
are relatively new drugs that clinicians may have less experience
with, these drugs are not associated with high malformation risks.
At present, lamotrigine is the drug of ﬁrst choice for women who
wish to become pregnant.13 In contrast, valproate and to a lesser
extent carbamazepine are associated with increased malformationrisks and especially neural tube defects.9,10,17 Also, the use of
valproate during pregnancy is associated with a decrease in
intelligence in exposed children compared to other AEDs.18–20 In
our opinion, the prescription of these drugs in pregnancy should be
surrounded with extreme caution. However, the use of these drugs
elicited less questions from either clinicians or patients than the
use of lamotrigine or levetiracetam. Questions concerning
intellectual development after prenatal exposure to AEDs were
not abundant in our inventory (5.1%, n = 11 out of 213 questions)
and were exclusively asked by healthcare professionals. Efforts
should be made to disseminate awareness of these data to
clinicians and women using AEDs.
Information demand was high for congenital malformations
risk in the newborn, indicating that both physicians and patients
were familiar with a possible causality related to AED exposure. It
is quite alarming that a substantial number of questions were
asked after onset of pregnancy, or even in the postnatal period of
the AED exposed child. Treatment adjustment during the
preconception phase of women using AEDs may result in a
decrease in malformation rate as compared to interventions during
a pregnancy.6 The second most enquired topic regarded updates
concerning speciﬁc AEDs without mentioning a speciﬁc pregnancy.
This question category reﬂects the need for continuous medical
education among clinicians in order to provide optimal care for
both women using AEDs and their offspring. The third most
frequently mentioned topic concerned AED associated neonatal
toxicity during breastfeeding, mainly for lamotrigine, levetirace-
tam and benzodiazepines. Drug transfer to breast milk and drug
half-life in infants appears to be most extensive for ethosuximide
and phenobarbitone.21 In contrast, investigations on the pharma-
cokinetics of lamotrigine and levetiracetam conducted so far
suggested minimal or no risk of toxicity in the neonate as a
consequence of breastfeeding.21,22 Concerns about these drugs are
not grounded and may be due to a lack of information on the topic.
The number of questions asked in total was not as high as might
be expected over a period of eight years (n = 222). Unfortunately,
we feel that this relatively low number reﬂects a lack of awareness
in the medical profession of the possible adverse consequences of
AED use during pregnancy. Therefore, women of reproductive age
may not have actively sought for information concerning the
possible adverse consequences of AED use in pregnancy.
Neurologists were the main group of health care professionals
to ask questions to the EURAP-NL coordinators. Neurology has long
led the way in developing and sharing information related to the
use of AEDs in women of childbearing age.12,13 Only a minority of
queries came from psychiatrists. This distribution is in agreement
with the participation rates from the EURAP registry since only
0.9% of women included were suffering from a disease other than
epilepsy.23 However, in daily medical practice especially older
generation AEDs (such as valproate) are often prescribed to female
patients by psychiatrists for mood stabilization.24 Valproate is the
AED with both an association with a high malformation rate and a
worse cognitive outcome in children exposed to valproate during
pregnancy.
Women being prescribed AED also asked a considerable
amount of questions (32.4% of all queries). Remarkably, one of
the reasons for them to ask information directly from EURAP-NL is
the opinion disagreement between their physicians. For example,
inconsistent advice was signalled when patients consulted two
neurologists, or a neurologist and a gynaecologist.
The present paper offers a description of the issues encountered
in medical practice when prescribing AEDs to pregnant women.
Caution should be taken when interpreting these observations as,
unlike a community-based assessment, our question inventory
had a participation bias. Therefore, it is highly likely that the
questions addressed to the EURAP only cover some areas of
A.E. Rapcencu et al. / Seizure 21 (2012) 606–609 609interest, while the ‘‘silent’’ patients and clinicians may have an
even broader information demand.
In conclusion, our study demonstrates the evident demand for
information regarding AEDs and pregnancy in both patients and
clinicians. The lack of information may result in divergent opinions
between clinicians and delayed counselling of women using AEDs.
Approaching registries like EURAP would be favourable to
counteract information deﬁcits in medical practice, and to develop
improved medical guidelines.
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